4.8 out of 5 stars
(5 Ratings)
Athena Security uses advanced concealed weapons detection systems to deliver a unified, AI-driven entryway solution for hospitals, K–12 schools, casinos, places of worship, government buildings, and commercial facilities across the U.S. The Apollo 500 enables seamless walk-through screening to detect weapons in real time, giving operators more actionable data points than traditional systems for faster, more confident decisions. Athena’s AI-powered X-ray leverages iPad technology to modernize screening and improve threat detection.
Athena’s Hospital Visitor Management System integrates with EPIC to connect identity, access, and screening data. Innovations include the Ambulance Bay WDS for stretcher screening and secondary screening for bags and lower extremities to reduce human error. Designed with compliance in mind, Athena aligns with California AB 2975, which mandates weapons detection screening at key hospital entrances by 2027 to improve safety and reduce workplace violence.
DHS-aligned workflows ensure testing, controls, and compliance, while telepresence and AR alert glasses provide real-time support. All systems connect in one platform for centralized monitoring and enterprise reporting.
Learn more about Athena Security
4.8 out of 5 stars
(5 Ratings)
Imorgon Report Accelerator, from Imorgon Medical, automates ultrasound reporting on the hospital's own servers. The scanner's measurements arrive by DICOM SR, and the sonographer's worksheet findings arrive with them, in the radiologist's PowerScribe, Fluency, Rad AI or Epic report, ready to review rather than dictate.
Key capabilities:
- Every scanner measurement transferred into the report's merge fields, usually by DICOM SR
- Site-customized electronic worksheets for every exam type
- Automatic priors and percent change
- Guideline calculations such as TI-RADS and O-RADS, by published rules (no AI)
- DXA (DEXA) report automation
- Vendor neutral across ultrasound scanner brands
- On-premises: patient data stays inside the hospital network
- Mappings maintained by Imorgon after go-live
Imorgon Medical was founded in 2006 by ultrasound industry leaders and is based in Sebastopol, California. Pricing is a setup fee plus a per-report charge.
Learn more about Imorgon
Infervision
Founded in 2016, Infervision stands at the forefront of AI-driven medical technology, dedicated to enhancing multidisciplinary healthcare services and operations through innovative artificial intelligence solutions. Their advanced AI offerings are designed to assist healthcare professionals across a spectrum of tasks, including disease screening, diagnosis, intervention, treatment, patient management, and medical research. Among their array of solutions, InferRead CT Lung specializes in detecting lung nodules from chest CT scans, while InferRead DR Chest focuses on identifying chest abnormalities via X-ray imaging. Moreover, InferRead CT Coronary is tailored for recognizing coronary artery stenosis during coronary CT angiography, and InferRead CT Stroke is adept at triaging hemorrhages from brain CT scans. The company also provides InferRead CT Bone for spotting chest fractures in CT images and InferRead CT Pneumonia for diagnosing and managing pneumonia cases. Beyond these, their offerings extend to InferOperate, which facilitates 3D reconstruction for thoracic, liver, and urological surgical procedures, and InferCare, a tool designed for effective patient management and image follow-up. Additionally, InferScholar acts as an AI-enhanced resource for medical research, further solidifying Infervision's commitment to transforming healthcare through AI technology. This comprehensive suite of solutions positions Infervision as a pivotal player in the evolution of medical practices.
Learn more about Infervision
Lunit
AI plays a crucial role in identifying early-stage cancers, facilitating prompt interventions that enhance survival prospects. Cancer's intricate nature means that each type carries distinct characteristics, packed with extensive data that requires thorough analysis. This is where AI excels, leveraging its capabilities to process complex information, ultimately revealing insights that can significantly aid in cancer treatment strategies. Equipped with precise and relevant data, we take proactive steps in our battle against cancer. By utilizing AI, we are poised to make substantial strides in overcoming this disease. Our AI technology is designed to detect early-stage cancer with remarkable accuracy, achieving detection rates between 97-99%. It proficiently identifies ten of the most prevalent abnormalities found in chest x-rays, thus enhancing one of the most fundamental diagnostic tools. This innovation not only streamlines the radiology workflow but also alleviates the workload for radiologists. Lunit INSIGHT CXR successfully encompasses a wide range of findings, ensuring that we are prepared to tackle the challenges presented by cancer detection and treatment. The future of cancer care looks promising with AI at the forefront of these advancements.
Learn more about Lunit